[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
    "summary": "Health care stocks were decreasing late Monday afternoon with the NYSE Health Care Index and the Hea",
    "url": "https://finnhub.io/api/news?id=b522a1078a77b6a152d26dc3ba99a95cf3e289fc3e784e72f6f7c4b7423d6929",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763413077,
      "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
      "id": 137522814,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Health care stocks were decreasing late Monday afternoon with the NYSE Health Care Index and the Hea",
      "url": "https://finnhub.io/api/news?id=b522a1078a77b6a152d26dc3ba99a95cf3e289fc3e784e72f6f7c4b7423d6929"
    }
  },
  {
    "ts": null,
    "headline": "Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point",
    "summary": "Get the latest on Tectonic Therapeutic, Inc.'s clinical progress in pulmonary hypertension and market potential. Click for key TECX milestones and industry outlook.",
    "url": "https://finnhub.io/api/news?id=cfda9fd89e21df24760e2c9374c57b37ef8aeed48ac90b45b2176c05d39ee5e0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763396549,
      "headline": "Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point",
      "id": 137509502,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2244150515/image_2244150515.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Get the latest on Tectonic Therapeutic, Inc.'s clinical progress in pulmonary hypertension and market potential. Click for key TECX milestones and industry outlook.",
      "url": "https://finnhub.io/api/news?id=cfda9fd89e21df24760e2c9374c57b37ef8aeed48ac90b45b2176c05d39ee5e0"
    }
  },
  {
    "ts": null,
    "headline": "MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026",
    "summary": "Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.",
    "url": "https://finnhub.io/api/news?id=e7f19a92ec4c599d1427d885c40fb20427a4ed9c6a76e26d88e16fbe9a0edef7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763386380,
      "headline": "MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026",
      "id": 137506439,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.",
      "url": "https://finnhub.io/api/news?id=e7f19a92ec4c599d1427d885c40fb20427a4ed9c6a76e26d88e16fbe9a0edef7"
    }
  },
  {
    "ts": null,
    "headline": "MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?",
    "summary": "Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.",
    "url": "https://finnhub.io/api/news?id=148a4a61e32365cc69658f4157fcfa8b509a3bacf92f327950cb52d964d01641",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763384700,
      "headline": "MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?",
      "id": 137506440,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.",
      "url": "https://finnhub.io/api/news?id=148a4a61e32365cc69658f4157fcfa8b509a3bacf92f327950cb52d964d01641"
    }
  },
  {
    "ts": null,
    "headline": "Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors",
    "summary": "SAN DIEGO, November 17, 2025--Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors",
    "url": "https://finnhub.io/api/news?id=1a28c02faf32d8f9e0e6925553237f71258b0ba1bf0e68abc2c133fce5ddeb90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763384400,
      "headline": "Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors",
      "id": 137506441,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "SAN DIEGO, November 17, 2025--Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors",
      "url": "https://finnhub.io/api/news?id=1a28c02faf32d8f9e0e6925553237f71258b0ba1bf0e68abc2c133fce5ddeb90"
    }
  },
  {
    "ts": null,
    "headline": "Cidara downgraded on Wall Street after Merck agrees to $9.2 billion buyout",
    "summary": "Investing.com -- Cidara Therapeutics was hit with broad downgrades after Merck agreed to buy the company for $221.50 a share in a deal valued at about $9.2 billion.",
    "url": "https://finnhub.io/api/news?id=822b03ce8e683ca1a3c43309127145a78cb3e2912b614348aedbf58236794cdf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763382709,
      "headline": "Cidara downgraded on Wall Street after Merck agrees to $9.2 billion buyout",
      "id": 137504163,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Investing.com -- Cidara Therapeutics was hit with broad downgrades after Merck agreed to buy the company for $221.50 a share in a deal valued at about $9.2 billion.",
      "url": "https://finnhub.io/api/news?id=822b03ce8e683ca1a3c43309127145a78cb3e2912b614348aedbf58236794cdf"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) M&A Call Transcript",
    "summary": "Merck & Co., Inc. (MRK) M&A Call November 17, 2025 8:00 AM ESTCompany ParticipantsPeter Dannenbaum - Vice President of Investor RelationsRobert...",
    "url": "https://finnhub.io/api/news?id=89bf1b6924c70e2d4e8b5f1488dd98bc958fe0454c5807e75c28f99ee3e62167",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763375227,
      "headline": "Merck & Co., Inc. (MRK) M&A Call Transcript",
      "id": 137504852,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck & Co., Inc. (MRK) M&A Call November 17, 2025 8:00 AM ESTCompany ParticipantsPeter Dannenbaum - Vice President of Investor RelationsRobert...",
      "url": "https://finnhub.io/api/news?id=89bf1b6924c70e2d4e8b5f1488dd98bc958fe0454c5807e75c28f99ee3e62167"
    }
  },
  {
    "ts": null,
    "headline": "iShares Biotechnology ETF: The M&A Wave Behind The Suddenly Booming Biotech Sector",
    "summary": "The biotech sector, tracked by iShares Biotechnology ETF, rallied 40% in six months on rising M&A activity, still below four-year levels. Read why IBB ETF is a hold.",
    "url": "https://finnhub.io/api/news?id=a93c9f715820a416f957440d371d00b46609b15bee750a6ce8d107460a587075",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763372660,
      "headline": "iShares Biotechnology ETF: The M&A Wave Behind The Suddenly Booming Biotech Sector",
      "id": 137504722,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184964962/image_184964962.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "The biotech sector, tracked by iShares Biotechnology ETF, rallied 40% in six months on rising M&A activity, still below four-year levels. Read why IBB ETF is a hold.",
      "url": "https://finnhub.io/api/news?id=a93c9f715820a416f957440d371d00b46609b15bee750a6ce8d107460a587075"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Cidara Therapeutics, Inc., - M&A Call - Slideshow",
    "summary": "2025-11-17. The following slide deck was published by Merck & Co., Inc.",
    "url": "https://finnhub.io/api/news?id=dbe85721ed1fc7e289457310c7a932146313c9faccc5b87211b8737d7b2144d6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763370108,
      "headline": "Merck & Co., Inc. (MRK) Cidara Therapeutics, Inc., - M&A Call - Slideshow",
      "id": 137504579,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "2025-11-17. The following slide deck was published by Merck & Co., Inc.",
      "url": "https://finnhub.io/api/news?id=dbe85721ed1fc7e289457310c7a932146313c9faccc5b87211b8737d7b2144d6"
    }
  },
  {
    "ts": null,
    "headline": "Solve lines up $120M to push ADCs into further testing",
    "summary": "The startup, which is backed by a dozen investors including Merck & Co., claims its novel “linkers” can help address some of the issues limiting the potential of earlier ADCs.",
    "url": "https://finnhub.io/api/news?id=22b0ea64f4a463c5d5391d8b9effd3dfc2567f9da822c111e550a1eb41fa5412",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763366400,
      "headline": "Solve lines up $120M to push ADCs into further testing",
      "id": 137506442,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The startup, which is backed by a dozen investors including Merck & Co., claims its novel “linkers” can help address some of the issues limiting the potential of earlier ADCs.",
      "url": "https://finnhub.io/api/news?id=22b0ea64f4a463c5d5391d8b9effd3dfc2567f9da822c111e550a1eb41fa5412"
    }
  },
  {
    "ts": null,
    "headline": "Goldman Sachs on brink of best M&A performance in 24 years",
    "summary": "Goldman Sachs is vying to capture its biggest share of the deals market in almost a quarter of a century, with Wall Street’s dominant investment...",
    "url": "https://finnhub.io/api/news?id=e1e0a3c31acf1885db52a78bcb95b977c1fcf3f42af65fe93e1105ebd6e0f844",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763355626,
      "headline": "Goldman Sachs on brink of best M&A performance in 24 years",
      "id": 137504160,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Goldman Sachs is vying to capture its biggest share of the deals market in almost a quarter of a century, with Wall Street’s dominant investment...",
      "url": "https://finnhub.io/api/news?id=e1e0a3c31acf1885db52a78bcb95b977c1fcf3f42af65fe93e1105ebd6e0f844"
    }
  },
  {
    "ts": null,
    "headline": "Merck And Royal Gold Among 13 Companies To Announce Annual Increases In Second Half Of November",
    "summary": "Dividend growth picked up from companies in the first half of November, with 6 companies announcing 10%+ increases. Learn more about the dividend growth here.",
    "url": "https://finnhub.io/api/news?id=dc17896625f148d3403a058f214dc6d2a62e3a8adfdf6db1e2addf6de64ae53d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763353910,
      "headline": "Merck And Royal Gold Among 13 Companies To Announce Annual Increases In Second Half Of November",
      "id": 137503246,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2206373039/image_2206373039.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Dividend growth picked up from companies in the first half of November, with 6 companies announcing 10%+ increases. Learn more about the dividend growth here.",
      "url": "https://finnhub.io/api/news?id=dc17896625f148d3403a058f214dc6d2a62e3a8adfdf6db1e2addf6de64ae53d"
    }
  }
]